October 3, 2022

Omicron booster: The UK becomes the first country to approve a vaccine targeting two different types of Covid-19

Omicron booster: The UK becomes the first country to approve a vaccine targeting two different types of Covid-19


The United Kingdom has become the first country to approve an updated version of Moderna’s booster vaccine for Covid-19 that targets two different types of coronavirus: the Omicron strain and the original virus from 2020.

“An updated version of Moderna’s COVID-19 vaccine that targets two different types of coronavirus (known as a ‘bivalent’ vaccine) for adult booster doses was approved today by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet The British regulator’s standards for safety, quality and efficacy,” an official government statement read on Monday.

She added that half of the booster, called “Spikevax bivalent Original/Omicron,” targets the original coronavirus strain while the other half targets Omicron.

The UK government said the decision to grant approval for the shot was supported by the MHRA, the government’s independent scientific advisory body, after carefully reviewing the evidence.

Approved after the results of a clinical trial, where Moderna mentioned His booster targeting Omicron showed a stronger immune response against the variant. The company said its updated booster also showed a “strong” response against the BA.4 and BA.5 sub-variants.

The side effects were described by MHRA as being similar to the original Moderna booster dose and found to be “moderate and self-curing.”

“No serious safety concerns have been identified,” the British government said in a statement.

Like Covid-19 continues to mutateMHRA CEO Dr. John Ryan said the new Moderna booster will help keep communities protected.

The first generation of COVID-19 vaccines used in the UK continues to provide important protection against disease and save lives. What this bivalent vaccine gives us is a sharp tool in our armory to help protect us from this disease while the virus continues to evolve.”

It is not yet clear who will be offered the booster drug and when. The UK Joint Committee on Immunization and Immunization (JCVI) will advise on the rollout of the vaccine.

Stefan Bancel, CEO of Moderna, He said On Twitter, he was “delighted” with the approval of the vaccine.

He said: “This represents the first authorization for a bivalent Omicron-containing bivalent vaccine, this bivalent vaccine playing an important role in protecting people in the UK from Covid-19 as the winter months enter.”